MedTrace Logo

Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm

NCT04312607 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2020-03-18

No results posted yet for this study

Summary

Evaluate diagnostic and prognostic value of CD26 positive stem cell Stem Cells in classic myeloproliferative neoplasms (MPNs).

To study CD26 expression on different phases of CML (chronic phase, accelerated phase, blastic phase).

To investigate whether CD26 positive stem cell are expressed only in Philadelphia chromosome positive MPN (CML) and/or in Philadelphia chromosome negative MPN (PV, ET, PMF).

Conditions

  • Myeloproliferative Neoplasm

Interventions

DIAGNOSTIC_TEST

BCR-ABL gene PCR

peripheral blood sampling for detection of Philadelphia chromosome and flowcytometry for detection of CD26 positive stem cells

Sponsors & Collaborators

  • Safaa AA Khaled

    lead OTHER

Principal Investigators

  • doha M ali, MD · Assiut University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2021-08-01
Completion
2022-03-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04312607 on ClinicalTrials.gov